 |
| AXXE Set To Soar on SmallCapVoice.com |
|
 Hot Stock to Watch |
Company: Axxess Pharma Inc. (Pink Sheets: AXXE)
|
Close:
Price: 0.88
Change (%): - 0.02 (2.22)
Volume: 1,604 |
 |
Axxess Pharma, Inc. Announces MOU for Exclusive World-Wide License Rights for TapouT Brand Vitamins and Pain Relief Products
Toronto, ON, July 23, 2013 - (eTeligis via Accesswire) - Axxess Pharma, Inc., (AXXE) a specialty pharmaceutical and nutritional supplements company, and TapouT (TAP) have entered into a Memorandum of Understanding (MOU) in which AXXE would receive world-wide exclusive rights, to market and sell a full line of pain relief and muscle recovery products, as well as develop and market a vitamin line under the TapouT brand.
Dr. Daniel Bagi, President of Axxess Pharma, Inc., stated, “This is an exciting time for our company. Our partnership with TapouT will provide AXXE with an additional six products that are ready to launch. Our initial goal, once the deal has been finalized, is to aggressively market this line of premium all-natural pain-relief products across North America. Shortly thereafter, launch globally as the TapouT brand gains footholds in other major countries such as Brazil, India and China. Global growth is anticipated to be fueled through TapouT’s sponsorship of MMA events. The second wave of TapouT branded products will be a premium vitamin line, which we anticipate launching in 2014.”
Dr. Bagi further stated, “We anticipate both TAP and AXXE will benefit tremendously from this alliance, as we recognize the power of the TapouT brand. We project closing the transaction over the course of the summer with a full-scale marketing campaign beginning during the fall quarter.”
Nick Woodhouse, President for TapouT/Authentic Brands Group stated, “We are very excited about this partnership with Axxess Pharma, Inc. We feel that Axxess incredible pain relief formulas are going to be well received by TapouT customers across North Amerca. As the TapouT brand continues to grow, Axxess will have an opportunity to grow with us.”
Continue Reading
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
|
